Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization

Current Diabetes Reports

Volumn 8, Issue 2, 2008, Pages 87-93

  Achenbach, Peter ^a   Barker, Jennifer ^b   Bonifacio, Ezio ^b  

^a INSTITUT FÜR DIABETESFORSCHUNG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CD4 ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; HLA DQ8 ANTIGEN; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; INSULIN; INTERLEUKIN 10; INTERLEUKIN 4; PANCREAS ISLET CELL ANTIBODY; PLACEBO; PROTEIN TYROSINE PHOSPHATASE; TRANSFORMING GROWTH FACTOR BETA;

ANTIBODY DETECTION; ANTIGEN SPECIFICITY; AUTOIMMUNITY; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CYTOKINE RELEASE; DISEASE COURSE; DISEASE MODEL; DRUG ADMINISTRATION ROUTE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSPOT ASSAY; FAMILY HISTORY; FOLLOW UP; GENETIC RISK; GENETIC SCREENING; GENOTYPE; HUMAN; IMMUNE RESPONSE; INSULIN DEPENDENT DIABETES MELLITUS; METHODOLOGY; MUCOSAL IMMUNITY; NONHUMAN; OPTIMAL DRUG DOSE; PATIENT SELECTION; PRIMARY PREVENTION; REVIEW; T LYMPHOCYTE; TREATMENT DURATION; BLOOD; CHILD; GENETICS; IMMUNIZATION; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, INTRANASAL; AUTOANTIBODIES; B-LYMPHOCYTES; CHILD; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNIZATION; INSULIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; T-LYMPHOCYTES;

EID: 44849138907     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-008-0017-y     Document Type: Review

References (56)

1. The DCCT/EDIC Research Group: Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003, 290:2159-2167.
2. Nathan DM, Lachin J, Cleary P, et al.: Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003, 348:2294-2303.
3. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group [no authors listed]. N Engl J Med 1993, 329:977-986.
4. Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. The Canadian-European Randomized Control Trial Group [no authors listed]. Diabetes 1988, 37:1574-1582.
5. Herold KC, Gitelman SE, Masharani U, et al.: Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002, 346:1692-1698.
6. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al.: Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005, 352:2598-2608.
7. Gale EA, Bingley pj, Emmert CL, Collier T. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004, 363:925-931.
8. Diabetes Prevention Trial - Type 1 Diabetes Study Group: Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002, 346:1685-1691.
9. Skyler JS, Krischer JP, Wolfsdorf J, et al.: Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial-Type 1. Diabetes Care 2005, 28:1068-1076.
10. French MB, Allison J, Cram DS, et al.: Transgenic expression of mouse proinsulin II prevents diabetes in nonobese diabetic mice. Diabetes 1997, 46:34-39.
11. Thebault-Baumont K, Dubois-Laforgue D, Krief P, et al.: Acceleration of type 1 diabetes mellitus in proinsulin 2-deficient NOD mice. J Clin Invest 2003, 111:851-857.
12. Moriyama H, Abiru N, Paronen J, et al.: Evidence for a primary islet autoantigen (preproinsulin 1) for insulitis and diabetes in the nonobese diabetic mouse. Proc Natl Acad Sci U S A 2003, 100:10376-10381.
13. Jaeckel E, Lipes MA, von Boehmer H: Recessive tolerance to preproinsulin 2 reduces but does not abolish type 1 diabetes. Nat Immunol 2004, 5:1028-1035.
14. Nakayama M, Abiru N, Moriyama H, et al.: Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 2005, 435:220-223.
15. Krishnamurthy B, Dudek NL, McKenzie MD, et al.: Responses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP. J Clin Invest 2006, 116:3258-3265.
16. Ziegler AG, Hummel M, Schenker M, Bonifacio E: Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 1999, 48:460-468.
17. Kimpimaki T, Kulmala P, Savola K, et al.: Natural history of beta-cell autoimmunity in young children with increased genetic susceptibility to type 1 diabetes recruited from the general population. J Clin Endocrinol Metab 2002, 87:4572-4579.
18. Barker JM, Barriga KJ, Yu L, et al.: Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). J Clin Endocrinol Metab 2004, 89:3896-3902.
19. Colman PG, Steele C, Couper JJ, et al.: Islet autoimmunity in infants with a type 1 diabetic relative is common but is frequently restricted to one autoantibody. Diabetologia 2000, 43:203-209.
20. Hummel M, Bonifacio E, Schmid S, et al.: Brief communication: early appearance of islet autoantibodies predicts childhood type 1 diabetes in offspring of diabetic parents. Ann Intern Med 2004, 140:882-886.
21. Kimpimaki T, Kupila A, Hamalainen AM, et al.: The first signs of beta-cell autoimmunity appear in infancy in genetically susceptible children from the general population: the Finnish Type 1 Diabetes Prediction and Prevention Study. J Clin Endocrinol Metab 2001, 86:4782-4788.
22. Yu L, Robles DT, Abiru N, et al.: Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. Proc Natl Acad Sci U S A 2000, 97:1701-1706.
23. Vardi P, Ziegler AG, Mathews JH, et al.: Concentration of insulin autoantibodies at onset of type 1 diabetes. Inverse log-linear correlation with age. Diabetes Care 1988, 11:736-739.
24. Kent SC, Chen Y, Bregoli L, et al.: Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. Nature 2005, 435:224-228.
25. Achenbach P, Koczwara K, Knopff A, et al.: Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J Clin Invest 2004, 114:589-597.
26. Chaillous L, Lefevre H, Thivolet C, et al.: Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabete Insuline Orale group. Lancet 2000, 356:545-549.
27. Pozzilli P, Pitocco D, Visalli N, et al.: No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group. Diabetologia 2000, 43:1000-1004.
28. Harrison LC, Honeyman MC, Steele CE, et al.: Pancreatic [beta)-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care 2004, 27:2348-2355.
29. Kupila A, Sipila J, Keskinen P, et al.: Intranasally administered insulin intended for prevention of type 1 diabetes - a safety study in healthy adults. Diabetes Metab Res Rev 2003, 19:415-420.
30. Faria AMC, Weiner HL: Oral tolerance. Immunol Rev 2005, 206:232-259.
31. Harrison LC, Hafler DA: Antigen-specific therapy for autoimmune disease. Curr Opin Immunol 2000, 12:704-711.
32. Gottlieb PA, Eisenbarth GS: Insulin-specific tolerance in diabetes. Clin Immunol 2002, 102:2-11.
33. Mayer L, Shao L: Therapeutic potential of oral tolerance. Nat Rev Immunol 2004, 4:407-419.
34. Bergerot I, Fabien N, Magner V, Thivolet C: Oral administration of human insulin to NOD mice generates CD4+ T cells that suppress adoptive transfer of diabetes. J Autoimmun 1994, 7:655-663.
35. Harrison LC, Dempsey-Collier M, Kramer DR, Takahashi K: Aerosol insulin induces regulatory CD8 gamma delta T cells that prevent murine insulin-dependent diabetes. J Exp Med 1996, 184:2167-2174.
36. Zhang ZJ, Davidson L, Eisenbarth G, Weiner HL: Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci U S A 1991, 88:10252-10256.
37. Maron R, Melican NS, Weiner HL: Regulatory Th2-type T cell lines against insulin and GAD peptides derived from orally- and nasally-treated NOD mice suppress diabetes. J Autoimmun 1999, 12:251-258.
38. Daniel D, Wegmann DR: Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc Natl Acad Sci U S A 1996, 93:956-960.
39. von Herrath MG, Dyrberg T, Oldstone MB: Oral insulin treatment suppresses virus-induced antigen-specific destruction of beta cells and prevents autoimmune diabetes in transgenic mice. J Clin Invest 1996, 98:1324-1331.
40. Hancock WW, Polanski M, Zhang J, et al.: Suppression of insulitis in non-obese diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, transforming growth factor-beta, and prostaglandin-E. Am J Pathol 1995, 147:1193-1199.
41. Bergerot I, Fabien N, Mayer A, Thivolet C: Active suppression of diabetes after oral administration of insulin is determined by antigen dosage. Ann N Y Acad Sci 1996, 778:362-367.
42. Maron R, Guerau-de-Arellano M, Zhang X, Weiner HL: Oral administration of insulin to neonates suppresses spontaneous and cyclophosphamide induced diabetes in the NOD mouse. J Autoimmun 2001, 16:21-28.
43. Monetini L, Cavallo MG, Sarugeri E, et al.: Cytokine profile and insulin antibody IgG subclasses in patients with recent onset type 1 diabetes treated with oral insulin. Diabetologia 2004, 47:1795-1802.
44. Weiner HL, Mackin GA, Matsui M, et al.: Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993, 259:1321-1324.
45. Trentham DE, Dynesius-Trentham RA, Orav EJ, et al.: Effects of oral administration of type II collagen on rheumatoid arthritis. Science 1993, 261:1727-1730.
46. Bonifacio E, Hummel M, Walter M, et al.: IDDM1 and multiple family history of type 1 diabetes combine to identify neonates at high risk for type 1 diabetes. Diabetes Care 2004, 27:2695-2700.
47. Aly TA, Ide A, Barker JM, et al.: HLA genotype and haplotype sharing determine extremely high risk of early childhood type 1 diabetes. Proc Natl Acad Sci U S A 2006, 103:14074-14079.
48. Walter M, Albert E, Conrad M, et al.: IDDM2/insulin VNTR modifies risk conferred by IDDM1/HLA for development of type 1 diabetes and associated autoimmunity. Diabetologia 2003, 46:712-720.
49. Laine AP, Hermann R, Knip M, et al.: The human leukocyte antigen genotype has a modest effect on the insulin gene polymorphism-associated susceptibility to type 1 diabetes in the Finnish population. Tissue Antigens 2004, 63:72-74.
50. Steck AK, Bugawan TL, Valdes AM, et al.: Association of non-HLA genes with type 1 diabetes autoimmunity. Diabetes 2005, 54:2482-2486.
51. Bonifacio E, Scripoli M, Kredel K, et al.: Early autoantibody responses in prediabetes are IgG1 dominated and suggest antigen-specific regulation. J Immunol 1999, 163:525-532.
52. Barker JM, McFann KK, Orban T: Effect of oral insulin on insulin autoantibody levels in the Diabetes Prevention Trial Type 1 oral insulin study. Diabetologia 2007, 50:1603-1606.
53. Roep BO: Standardization of T-cell assays in Type I diabetes. Immunology of Diabetes Society T-cefl Committee. Diabetologia 1999, 42:636-637.
54. Arif S, Tree TI, Astill TP, et al.: Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest 2004, 113:451-463.
55. Danke NA, Yang J, Greenbaum C, Kwok WW: Comparative study of GAD65-specific CD4+ T cells in healthy and type 1 diabetic subjects. J Autoimmun 2005, 25:303-311.
56. Monti P, Scripoli M, Rigamonti A, et al.: Evidence for in vivo primed and expanded autoreactive T cells as a specific feature of patients with type 1 diabetes. J Immunol 2007, 179:5785-5792.